Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifetroban in Diffuse Cutaneous Systemic Sclerosis or SSc-associated Pulmonary Arterial Hypertension
NCT02682511Phase 2Active, not recruiting
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ifetroban in systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH) (2 arms), sponsored by Cumberland Pharmaceuticals. Primary endpoint: Incidence of adverse events and Serious AEs at 56 weeks. Started Jan 2017; status: active, not recruiting.
02
Drugs
ifetroban
03
Conditions
systemic sclerosis (SSc)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02682511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682511.